EFFICACY AND SAFETY OF COTADUTIDE, A DUAL GLP1-GLUCAGON RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND T2DM

被引：0
|
作者：
Selvarajah, Viknesh [1 ]
Robertson, Darren [1 ]
Hansen, Lars [2 ]
Jermutus, Lutz [1 ]
Smith, Kirsten [1 ]
Frickleton, Celeste [2 ]
Coggi, Angela [1 ]
Sanchez, Jose [3 ]
Chang, Yi-Ting [2 ]
Parker, Victoria [1 ]
机构：
[1] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Cambridge, England
[2] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Gaithersburg, MD USA
[3] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Molndal, Sweden
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
3000
引用
收藏
页码：I87 / I87
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD
    Parker, Victoria E.
    Hoang, Thuong
    Schlichthaar, Heike
    Gibb, Fraser W.
    Wenzel, Barbara
    Posch, Maximilian G.
    Chang, Yi-Ting
    Petrone, Marcella
    Hansen, Lars
    Ambery, Philip
    Heerspink, Hiddo L.
    Mccrimmon, Rory J.
    Jermutus, Lutz
    DIABETES, 2021, 70
  • [2] Efficacy of cotadutide dual GLP1-glucagon receptor agonist on albuminuria and glycaemic control in patients with diabetic kidney disease
    Robertson, D.
    Selverajah, V.
    Hansen, L.
    Jermutus, L.
    Smith, K.
    Frickleton, C.
    Coggi, A.
    Sanchez, J.
    Chang, Y-T
    Parker, V. E. R.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S32 - S32
  • [3] Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease
    Aldrich, Sarah
    Ashjian, Emily
    NURSE PRACTITIONER, 2019, 44 (03): : 20 - 28
  • [4] Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
    Parker, Victoria E. R.
    Hoang, Thuong
    Schlichthaar, Heike
    Gibb, Fraser W.
    Wenzel, Barbara
    Posch, Maximillian G.
    Rose, Ludger
    Chang, Yi-Ting
    Petrone, Marcella
    Hansen, Lars
    Ambery, Philip
    Jermutus, Lutz
    Heerspink, Hiddo J. L.
    McCrimmon, Rory J.
    DIABETES OBESITY & METABOLISM, 2022, 24 (07): : 1360 - 1369
  • [5] Immunogenicity, Safety, and Efficacy of Influenza Vaccine in T2DM and T2DM with Chronic Kidney Disease
    Heryaman, Henhen
    Juli, Cep
    Nazir, Arnengsih
    Syamsunarno, Mas Rizky A. A.
    Yahaya, Badrul Hisham
    Turbawaty, Dewi Kartika
    Sari, Rini Mulia
    Permana, Hikmat
    Supriyadi, Rudi
    Atik, Nur
    VACCINES, 2024, 12 (03)
  • [6] The Long-Term Efficacy and Safety of Canagliflozin in Combination with GLP-1 Receptor Agonist In Japanese Patients with T2DM
    Harashima, Shinichi
    Inagaki, Nobuya
    Kondo, Kazuoki
    Maruyama, Nobuko
    Otsuka, Makiko
    Kawaguchi, Yutaka
    Iijima, Hiroaki
    Goda, Maki
    Watanabe, Yumi
    DIABETES, 2017, 66 : A318 - A319
  • [7] Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist
    Parker, Victoria E. R.
    Robertson, Darren
    Wang, Tao
    Hornigold, David C.
    Petrone, Marcella
    Cooper, Aidan T.
    Posch, Maximilian G.
    Heise, Tim
    Plum-Moerschel, Leona
    Schlichthaar, Heike
    Klaus, Beate
    Ambery, Philip D.
    Meier, Juris J.
    Hirshberg, Boaz
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (03): : 803 - 820
  • [8] Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (<600 μG) with Robust Effects on Blood Glucose in Patients with T2DM
    Robertson, Darren
    Hansen, Lars
    Jain, Meena
    Parker, Victoria
    Petrone, Marcella
    Wang, Tao
    Heise, Tim
    Jermutus, Lutz
    DIABETES, 2020, 69
  • [9] Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM
    Ohwaki, Kenji
    Furihata, Kenichi
    Mimura, Hanaka
    Oura, Tomonori
    Imaoka, Takeshi
    DIABETES, 2019, 68
  • [10] Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycemic control and body weight in Japanese patients with T2DM
    Ohwaki, Kenji
    Furihata, Kenichi
    Mimura, Hanaka
    Oura, Tomonori
    Imaoka, Takeshi
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
12345